Genomics in Hematology: Redefining Diagnosis and Therapy at Fortis Institute of Genomic Medicine

At the heart of every blood cancer lies a unique molecular code. Today, we can decode it.

The convergence of genomics and hematology is no longer a futuristic promise—it’s transforming patient care right now. From diagnosing cryptic leukemias to predicting treatment response and transplant outcomes, genomic testing has become indispensable in the hematology and hemato-oncology landscape.

At the Fortis Institute of Genomic Medicine, we bring this cutting-edge science to life—one genome at a time.

Why Genomics Matters in Hematology

Hematologic malignancies like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), lymphomas, and myeloproliferative neoplasms (MPNs) are fundamentally driven by genetic alterations. These include point mutations, insertions/deletions, gene fusions, and chromosomal rearrangements that shape the biology, prognosis, and therapeutic choices in each case.

Thanks to innovations like next-generation sequencing (NGS), digital PCR, and low-pass whole genome sequencing, we now detect even the subtlest of molecular aberrations with unprecedented speed and accuracy.

From Microscope to Molecule: A Diagnostic Revolution
Gone are the days when morphology and immunophenotyping alone defined a diagnosis. The WHO 5th Edition and International Consensus Classification mandate the integration of molecular genetics in defining hematologic neoplasms.

At Fortis, our genomics-first approach enables:

• Early and Accurate Diagnosis

  Cryptic rearrangements like KMT2A, NUP98, or ETV6 fusions are now identified upfront, even in patients with ambiguous morphology or normal karyotypes

• Personalized Treatment Planning

  Molecular profiling allows us to select targeted therapies—like FLT3 inhibitors, IDH1/2 inhibitors, TP53 modulators—and stratify patients for transplant or CAR-T therapy.

• Prognostication Beyond Morphology

  Genomic risk stratification, as per ELN 2022 or NCCN guidelines, offers far more accurate survival predictions than traditional staging systems.

Real-World Genomics, Real-Time Impact

Our ultrafast turnaround times—often within 48 to 72 hours—mean that patients no longer wait weeks for critical decisions. Whether it’s confirming core-binding factor AML, identifying CHIP mutations, or guiding a transplant protocol, our reports are clinically actionable and delivered by experts.

We’ve recently completed the largest single-institution prospective NGS study in AML in India, bringing forth Indian-specific data on mutation patterns, fusion landscapes, and CHIP prevalence.

What Makes the Fortis Institute Unique

• Comprehensive Panels tailored for leukemia, lymphoma, MDS, and transplant genomics
• AI-driven analysis with deep bioinformatics support
• Integrated multidisciplinary reporting, including molecular tumor boards
• Dynamic ctDNA monitoring for response evaluation during chemotherapy and CAR-T therapy
• Genomic counseling for inherited cancer syndromes and donor selection

A Future Shaped by Data and Driven by Compassion

As we continue to bridge science and care, genomics becomes more than a test—it becomes a lens through which we understand disease and personalize healing.

At the Fortis Institute of Genomic Medicine, we believe that every mutation tells a story—and every patient deserves to know theirs.